Could less chemo be enough? new trial aims to treat High-Risk neuroblastoma with reduced therapy
NCT ID NCT06528496
First seen Nov 10, 2025 · Last updated Jun 19, 2026 · Updated 21 times
Summary
This phase 2 trial is testing whether a reduced chemotherapy regimen called N10 is safe and effective for children with high-risk neuroblastoma. The study will enroll 45 children under 19 years old who have not had more than one prior chemo cycle. The goal is to see if this lighter approach can still achieve a complete response while potentially causing fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N10 chemotherapy (naxitamab, sargramostim, cyclophosphamide, topotecan, vincristine)
What this could lead to
If successful, this could lead to a less intensive treatment option for children with high-risk neuroblastoma, potentially reducing side effects while maintaining effectiveness.
What could go wrong
This is a small, early-phase trial with only 45 participants, so results may not apply to all patients. The reduced therapy might be less effective or still cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.